Literature DB >> 3197365

Disposition of a flow-limited drug (lidocaine) and a metabolic capacity-limited drug (theophylline) in liver cirrhosis.

A Colli1, G Buccino, M Cocciolo, R Parravicini, G Scaltrini.   

Abstract

The plasma clearance after oral administration of a completely absorbed drug that is metabolized by the liver depends on its intrinsic clearance. In cirrhosis the bioavailability of a flow-dependent drug increases because of both portosystemic shunting and hepatocyte dysfunction. A drug with a high extraction ratio, lidocaine, and a drug with a low extraction ratio, theophylline, were administered to 27 patients with cirrhosis and 16 control subjects. We found a significant impairment of both theophylline clearance (p less than 0.001) and lidocaine clearance (p less than 0.001) and an increase in the lidocaine peak concentration (p less than 0.001). The three parameters were significantly correlated with each other. The impairment of theophylline metabolism did not correlate with other indexes of disease severity, whereas lidocaine clearance was lower and lidocaine peak level higher in patients with decompensated cirrhosis and evidence of portal hypertension. Thus impairment in lidocaine disposition, which reflects both hepatocyte dysfunction and portosystemic shunting, correlated closer with the severity of liver disease than did theophylline metabolism.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3197365     DOI: 10.1038/clpt.1988.206

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  13 in total

Review 1.  Clinical pharmacokinetics in patients with liver disease.

Authors:  A J McLean; D J Morgan
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

Review 2.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

3.  Lidocaine and monoethylglycinexylidide serum determinations to analyze liver function of cirrhotic patients after oral administration.

Authors:  A E Muñoz; C Miguez; M Rubio; M Bartellini; D Levi; A Podestá; V Niselman; R Terg
Journal:  Dig Dis Sci       Date:  1999-04       Impact factor: 3.199

4.  Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with hepatic cirrhosis.

Authors:  W L Hayton; J Kneer; R A Blouin; K Stoeckel
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

5.  Influence of age, frailty and liver function on the pharmacokinetics of brofaromine.

Authors:  J Zeeh; L Fuchs; W Bergmann; K H Antonin; F Degel; P Bieck; D Platt
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

Review 6.  Effect of hepatic insufficiency on pharmacokinetics and drug dosing.

Authors:  R K Verbeeck; Y Horsmans
Journal:  Pharm World Sci       Date:  1998-10

Review 7.  Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.

Authors:  Roger K Verbeeck
Journal:  Eur J Clin Pharmacol       Date:  2008-09-02       Impact factor: 2.953

Review 8.  Antiarrhythmics: elimination and dosage considerations in hepatic impairment.

Authors:  Ulrich Klotz
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 9.  Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update.

Authors:  D J Morgan; A J McLean
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

Review 10.  Pharmacokinetic changes in patients with oedema.

Authors:  B Vrhovac; N Sarapa; I Bakran; M Huic; V Macolic-Sarinic; I Francetic; A Wolf-Coporda; F Plavsic
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.